The debut of troglitazone, a potent glucose-lowering agent, marked a important chapter in the treatment of type 2 diabetes. However, its withdrawal from the market due to severe hepatotoxicity spurred broad investigation into related thiazolidinediones. Subsequently pioglitazone and rosiglitazone emerged, offering analogous mechanisms of action –